AI Article Synopsis
- A total of 3,164 patients with advanced cancer received dendritic cell therapy from July 2005 to March 2020, showing an overall effectiveness rate of 19.0% for those treated more than 3 times.
- Among 133 patients treated with a combination of immune checkpoint inhibitors and dendritic cell therapy during the study period, the effectiveness rate rose significantly to 54.1%.
- For 98 patients receiving dendritic cell therapy with neoantigens, the effectiveness rate was 38.7%, compared to 18.3% for those without neoantigens, indicating that combining both immune checkpoint inhibitors and neoantigens further improved the effectiveness to 60.7%.
Article Abstract
We treated 3,164 patients with advanced cancer with dendritic cell therapy between July 2005 and March 2020. The effective rate in patients treated with dendritic cell therapy more than 3 times was 19.0%. Among them, we treated 133 cancer patients with a combination of immune checkpoint inhibitors and dendritic cell therapy between June 2015 and March 2020. The effective rate in these patients was 54.1%. We treated 98 cancer patients with dendritic cell therapy with neoantigens between March 2018 and March 2020. The effective rate in these patients treated with neoantigens was 38.7%. The effective rate in patients treated without neoantigens was 18.3%. Dendritic cell therapy with neoantigens enhanced the effective rate. The effective rate of dendritic cell therapy with both immune checkpoint inhibitors and neoantigens was 60.7%.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!